Halozyme Therapeutics, Inc. insider trading
HALOfinancial statementsForm 4 filings on EDGAR309 transactions since Nov 3, 2024
From August 6, 2026 to November 3, 2026, 0 insiders at Halozyme Therapeutics, Inc. bought $0 of stock in the open market, and 3 sold $22M. Officers and directors accounted for $0 of purchases and $22M of sales. The last reported transaction was an option exercise by Torley Helen on October 8, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through October 8, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $22MAug 6, 2026 – Nov 3, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Nov 3, 2026. Insider data through Nov 3, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
309 transactions from November 3, 2024 to November 3, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | Torley Helen | PRESIDENT AND CEO, Director | option exercise | 20,000 | $18.41 | $368K | 787,780 | Oct 8, 2026 |
| Oct 8, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 4,810 | $108.18 | $520K | 782,970 | Oct 8, 2026 |
| Oct 8, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 3,090 | $108.91 | $337K | 779,880 | Oct 8, 2026 |
| Oct 8, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 11,900 | $110.00 | $1M | 767,980 | Oct 8, 2026 |
| Oct 8, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 200 | $110.51 | $22K | 767,780 | Oct 8, 2026 |
| Oct 7, 2026 | Torley Helen | PRESIDENT AND CEO, Director | option exercise | 20,000 | $18.41 | $368K | 787,780 | Oct 8, 2026 |
| Oct 7, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 8,600 | $111.03 | $955K | 779,180 | Oct 8, 2026 |
| Oct 7, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 10,300 | $111.84 | $1M | 768,880 | Oct 8, 2026 |
| Oct 7, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 900 | $112.78 | $102K | 767,980 | Oct 8, 2026 |
| Oct 7, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 200 | $113.69 | $23K | 767,780 | Oct 8, 2026 |
| Oct 6, 2026 | Torley Helen | PRESIDENT AND CEO, Director | option exercise | 20,000 | $18.41 | $368K | 787,780 | Oct 8, 2026 |
| Oct 6, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 2,300 | $107.90 | $248K | 785,480 | Oct 8, 2026 |
| Oct 6, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 6,000 | $109.33 | $656K | 779,480 | Oct 8, 2026 |
| Oct 6, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 9,920 | $109.89 | $1M | 769,560 | Oct 8, 2026 |
| Oct 6, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 1,780 | $110.81 | $197K | 767,780 | Oct 8, 2026 |
| Oct 1, 2026 | Daly James M | Director | award | 1,169 | $0.00 | — | 1,169 | Oct 2, 2026 |
| Oct 1, 2026 | Posard Matthew L. | Director | open-market sale10b5-1 | 730 | $107.17 | $78K | 58,109 | Oct 2, 2026 |
| Oct 1, 2026 | Posard Matthew L. | Director | open-market sale10b5-1 | 3,300 | $108.45 | $358K | 54,809 | Oct 2, 2026 |
| Oct 1, 2026 | Posard Matthew L. | Director | open-market sale10b5-1 | 1,100 | $109.57 | $121K | 53,709 | Oct 2, 2026 |
| Oct 1, 2026 | Posard Matthew L. | Director | open-market sale10b5-1 | 100 | $110.04 | $11K | 53,609 | Oct 2, 2026 |
| Sep 16, 2026 | Posard Matthew L. | Director | open-market sale10b5-1 | 3,100 | $106.13 | $329K | 74,735 | Sep 17, 2026 |
| Sep 16, 2026 | Posard Matthew L. | Director | open-market sale10b5-1 | 3,000 | $106.83 | $320K | 71,735 | Sep 17, 2026 |
| Sep 16, 2026 | Posard Matthew L. | Director | open-market sale10b5-1 | 8,896 | $108.04 | $961K | 62,839 | Sep 17, 2026 |
| Sep 16, 2026 | Posard Matthew L. | Director | open-market sale10b5-1 | 4,000 | $108.99 | $436K | 58,839 | Sep 17, 2026 |
| Sep 11, 2026 | Torley Helen | PRESIDENT AND CEO, Director | option exercise | 20,000 | $18.41 | $368K | 787,780 | Sep 11, 2026 |
| Sep 11, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 15,492 | $107.15 | $2M | 772,288 | Sep 11, 2026 |
| Sep 11, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 4,508 | $107.55 | $485K | 767,780 | Sep 11, 2026 |
| Sep 10, 2026 | Torley Helen | PRESIDENT AND CEO, Director | option exercise | 20,000 | $18.41 | $368K | 787,780 | Sep 11, 2026 |
| Sep 10, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 14,588 | $107.01 | $2M | 773,192 | Sep 11, 2026 |
| Sep 10, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 5,412 | $107.58 | $582K | 767,780 | Sep 11, 2026 |
| Sep 9, 2026 | Torley Helen | PRESIDENT AND CEO, Director | option exercise | 20,000 | $18.41 | $368K | 787,780 | Sep 11, 2026 |
| Sep 9, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 13,304 | $107.22 | $1M | 774,476 | Sep 11, 2026 |
| Sep 9, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 6,596 | $107.82 | $711K | 767,880 | Sep 11, 2026 |
| Sep 9, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 100 | $108.67 | $11K | 767,780 | Sep 11, 2026 |
| Sep 1, 2026 | Appelhans Dannielle | Director | award | 1,161 | $0.00 | — | 1,161 | Sep 2, 2026 |
| Aug 19, 2026 | Torley Helen | PRESIDENT AND CEO, Director | option exercise | 20,000 | $18.41 | $368K | 787,780 | Aug 19, 2026 |
| Aug 19, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 7,200 | $106.36 | $766K | 780,580 | Aug 19, 2026 |
| Aug 19, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 9,600 | $107.22 | $1M | 770,980 | Aug 19, 2026 |
| Aug 19, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 3,200 | $107.77 | $345K | 767,780 | Aug 19, 2026 |
| Aug 18, 2026 | Torley Helen | PRESIDENT AND CEO, Director | option exercise | 20,000 | $18.41 | $368K | 787,780 | Aug 19, 2026 |
| Aug 18, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 5,703 | $103.08 | $588K | 782,077 | Aug 19, 2026 |
| Aug 18, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 4,897 | $104.11 | $510K | 777,180 | Aug 19, 2026 |
| Aug 18, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 9,400 | $104.87 | $986K | 767,780 | Aug 19, 2026 |
| Aug 17, 2026 | Torley Helen | PRESIDENT AND CEO, Director | option exercise | 20,000 | $18.41 | $368K | 787,780 | Aug 19, 2026 |
| Aug 17, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 900 | $98.96 | $89K | 786,880 | Aug 19, 2026 |
| Aug 17, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 500 | $100.46 | $50K | 786,380 | Aug 19, 2026 |
| Aug 17, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 2,100 | $101.77 | $214K | 784,280 | Aug 19, 2026 |
| Aug 17, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 9,000 | $102.55 | $923K | 775,280 | Aug 19, 2026 |
| Aug 17, 2026 | Torley Helen | PRESIDENT AND CEO, Director | open-market sale10b5-1 | 7,500 | $103.48 | $776K | 767,780 | Aug 19, 2026 |
| Aug 10, 2026 | Connaughton Bernadette | Director | open-market sale10b5-1 | 1,626 | $102.80 | $167K | 40,418 | Aug 11, 2026 |
Who the insiders are
Everyone who reported a transaction since November 3, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO, Director | Oct 8, 2026 | option exercise | 787,780 | — | $42M (85) | 85 of 85 |
| Posard Matthew L. | Director | Oct 1, 2026 | open-market sale | 58,109 | — | $3M (8) | 8 of 8 |
| Caudill Cortney | SVP, CHIEF OPERATING OFFICER | Mar 10, 2026 | open-market sale | 7,055 | — | $2M (3) | 0 of 3 |
| Connaughton Bernadette | Director | Aug 10, 2026 | open-market sale | 40,418 | — | $839K (8) | 8 of 8 |
| Krishnan Mahesh | Director | Jun 29, 2026 | option exercise | 21,766 | — | $548K (1) | 1 of 1 |
| LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | Feb 23, 2026 | tax withholding | 38,494 | — | — | — |
| Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | Jun 12, 2026 | option exercise | 52,644 | — | — | — |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | Feb 27, 2025 | open-market sale | 173,856 | — | — | — |
| Henderson Jeffrey William | Director | May 5, 2026 | award | 36,572 | — | — | — |
| Ramsay David A | EVP, PRESIDENT, DRUG DELIVERY | Jun 30, 2026 | option exercise | 10,000 | — | — | — |
| Lang James Paul | Director | May 5, 2026 | award | 4,685 | — | — | — |
| Duncan Barbara Gayle | Director | May 5, 2026 | award | 23,715 | — | — | — |
| Daly James M | Director | Oct 1, 2026 | award | 1,169 | — | — | — |
| Appelhans Dannielle | Director | Sep 1, 2026 | award | 1,161 | — | — | — |
| Miyashita Akiko Moni | Director | May 1, 2025 | award | 24,937 | — | — | — |
| Matsui Connie | Director | Nov 29, 2024 | gift | 183,035 | — | — | — |
Questions
Are Halozyme Therapeutics, Inc. insiders buying or selling?
Over the twelve months to November 3, 2026, 5 insiders at Halozyme Therapeutics, Inc. sold $48M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $48M. Only open-market purchases and sales are counted.
Who sold the most Halozyme Therapeutics, Inc. stock in the last year?
Torley Helen (PRESIDENT AND CEO, Director) sold $42M in 85 open-market sales over the twelve months to November 3, 2026.
Do Halozyme Therapeutics, Inc. executives sell under 10b5-1 plans?
102 of the 105 open-market sales in the last twelve months (97%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Halozyme Therapeutics, Inc.
- Halozyme Therapeutics, Inc. financial statements
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.